BRPI0610824A8 - Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos - Google Patents

Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos

Info

Publication number
BRPI0610824A8
BRPI0610824A8 BRPI0610824A BRPI0610824A BRPI0610824A8 BR PI0610824 A8 BRPI0610824 A8 BR PI0610824A8 BR PI0610824 A BRPI0610824 A BR PI0610824A BR PI0610824 A BRPI0610824 A BR PI0610824A BR PI0610824 A8 BRPI0610824 A8 BR PI0610824A8
Authority
BR
Brazil
Prior art keywords
compounds
composition containing
purine derivative
derivative compounds
necessarily equal
Prior art date
Application number
BRPI0610824A
Other languages
English (en)
Inventor
Fortin Daniel
Penney Christopher
Zacharie Boulos
Wilb Nicole
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of BRPI0610824A2 publication Critical patent/BRPI0610824A2/pt
Publication of BRPI0610824A8 publication Critical patent/BRPI0610824A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTOS DERIVADOS DE PURINA, USO DOS MESMOS E COMPOSIÇÃO CONTENDO OS REFERIDOS COMPOSTOS. Compostos úteis no tratamento de doença auto-imune são descritos pela seguinte fórmula geral: n = 0-2 m = 0-2 m não é necessariamente igual a n onde R1, R3 = NH2, F, CI, grupo C1-C4 alcóxi ou fenóxi, mas R1 é não necessariamente igual a R3; e R2= H, F, Cl, NH2, ou NH-R-XH; onde R = -(CH2)p- p = 2 a 4 X = CH2, NH, O, ou S.
BRPI0610824A 2005-05-16 2006-05-15 Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos BRPI0610824A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68114105P 2005-05-16 2005-05-16
US60/681,141 2005-05-16
PCT/CA2006/000783 WO2006136005A1 (en) 2005-05-16 2006-05-15 Purine derivatives and their use for treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
BRPI0610824A2 BRPI0610824A2 (pt) 2010-07-27
BRPI0610824A8 true BRPI0610824A8 (pt) 2017-04-04

Family

ID=37570052

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610824A BRPI0610824A8 (pt) 2005-05-16 2006-05-15 Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos

Country Status (8)

Country Link
US (1) US8080555B2 (pt)
EP (1) EP1881987B1 (pt)
JP (1) JP5108752B2 (pt)
AU (1) AU2006261527B2 (pt)
BR (1) BRPI0610824A8 (pt)
CA (1) CA2608314C (pt)
MX (1) MX2007014297A (pt)
WO (1) WO2006136005A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003301407B2 (en) * 2002-10-15 2010-04-22 Irm Llc Compositions and methods for inducing osteogenesis
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
CN103288682B (zh) * 2012-02-25 2016-06-22 浙江华海药业股份有限公司 一种简便的纯化(4-氨基苯基)氨基甲酸叔丁酯的方法
EP2841562B1 (en) 2012-04-25 2020-06-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Methods of producing and using regulatory b-cells
AU2020295470B2 (en) 2019-06-18 2025-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interleukin-27 producing B-cells and uses thereof
JP2024503046A (ja) 2021-01-11 2024-01-24 アメリカ合衆国 Ｉｌ－３５又はｉｌ－２７を含むエクソソーム及びその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
IL144675A0 (en) * 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
ATE345349T1 (de) * 1999-12-17 2006-12-15 Ariad Pharma Inc Purinderivate
WO2001044260A2 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
US7115589B2 (en) * 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2002334992B2 (en) * 2001-10-12 2009-07-02 Irm Llc Methods for the synthesis of substituted purines
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
ES2361835T3 (es) * 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
AU2005218655A1 (en) * 2004-03-02 2005-09-15 Neurogen Corporation Aryl substituted purine analogues

Also Published As

Publication number Publication date
AU2006261527B2 (en) 2012-11-22
JP5108752B2 (ja) 2012-12-26
US8080555B2 (en) 2011-12-20
WO2006136005A1 (en) 2006-12-28
CA2608314C (en) 2015-10-27
JP2008540583A (ja) 2008-11-20
EP1881987A4 (en) 2014-08-13
AU2006261527A1 (en) 2006-12-28
CA2608314A1 (en) 2006-12-28
US20090042768A1 (en) 2009-02-12
MX2007014297A (es) 2008-04-21
EP1881987A1 (en) 2008-01-30
EP1881987B1 (en) 2016-10-19
BRPI0610824A2 (pt) 2010-07-27

Similar Documents

Publication Publication Date Title
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
DE60328010D1 (de) Heterocyclische verbindungen
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
ATE484508T1 (de) Furylverbindungen
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
EA200401199A1 (ru) Ингибиторы гистондеацетилазы
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
EA200301289A1 (ru) Новые производные пиррола в качестве фармацевтических средств
BRPI0407827A (pt) compostos de aminoeteroarila como inibidores de proteìna cinase
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
DE60333746D1 (de) Thienylverbindungen
BRPI0508464B8 (pt) sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
DOP2002000447A (es) 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5 onas como inhibidores de fosfodiesterasas
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
BRPI0406646A (pt) Compostos de(2-carboxamido)(3-amina)tiofenos, bem como composições e usos compreendendo os mesmos
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PROMETIC PHARMA SMT LIMITED (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.